Hydrocortisone tablets: alleged anti-competitive agreements and abusive conduct

The CMA is investigating alleged anti-competitive agreements and abusive conduct with respect to hydrocortisone tablets under Chapters I and II CA98 and Articles 101 and 102 TFEU.

Case timetable

Date Action
May 2017 to June 2019 (estimate) Further evidence gathering and analysis
April to May 2017 Receipt of written and oral representations on the statement of objections
March 2017 Statement of objections issued
September 2016 to February 2017 Further information gathering and analysis of information requests
September 2016 Decision to continue with the investigation
August 2016 to September 2016 Investigation and analysis including further information requests and stakeholder meetings
April 2016 to July 2016 Initial investigation: information gathering, including issuance of formal or informal information requests and parties’ responses. CMA analysis and review of parties’ responses to information requests. Potential state of play meetings with parties under investigation
April 2016 Investigation opened

Statement of objections

3 March 2017: The CMA issued a statement of objections alleging that Concordia and Actavis UK have breached UK and EU competition law by entering into anti-competitive agreements in relation to the supply of hydrocortisone tablets in the UK. In doing so, the CMA also alleges that Actavis UK abused its dominant position by inducing Concordia not to enter the market independently in the UK market.


  • The investigation is under Chapter I and Chapter II of the Competition Act 1998 (CA98) and Articles 101 and 102 of the Treaty on the Functioning of the European Union (TFEU).
  • No conclusion should be drawn that there has been an infringement of competition law at this stage and the recipients of the statement of objections will now have the opportunity to respond to the allegations.
  • The CMA will consider any representations it receives before any decision is taken as to whether competition law has in fact been infringed.
  • Changes to the timing of original entries in the case timetable will be made where the estimated timing changes.


Assistant Project Director

Louise Banér (020 3738 6056, louise.baner@cma.gov.uk)

Project Director and Senior Responsible Officer

Andrew Groves (0203 738 6927, andrew.groves@cma.gov.uk)

Published 12 April 2016
Last updated 20 November 2018 + show all updates
  1. Case timetable updated.
  2. Statement of objections issued
  3. Timetable updated.
  4. Timetable updated.
  5. First published.